Beyond the Golden Hour: Treating Acute Stroke in the Platinum 30 Minutes.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
08 2022
Historique:
pubmed: 13 5 2022
medline: 28 7 2022
entrez: 12 5 2022
Statut: ppublish

Résumé

To emphasize treatment speed for time-sensitive conditions, emergency medicine has developed not only the concept of the golden hour, but also the platinum half-hour. Patients with acute stroke treated within the first half-hour of onset have not been previously characterized. In this cohort study, we analyzed patients enrolled in the FAST-MAG (Field Administration of Stroke Therapy-Magnesium) trial, testing paramedic prehospital start of neuroprotective agent ≤2 hours of onset. The features of all acute cerebral ischemia, and intracranial hemorrhage patients with treatment starting at ≤30 m of last known well were compared with later-treated patients. Among 1680 patients, 203 (12.1%) received study agents within 30 minutes of last known well. Among platinum half-hour patients, median onset-to-treatment time was 28 minutes (interquartile range, 25-30), and final diagnoses were acute cerebral ischemia in 71.8% (ischemic stroke, 61.5%, TIA 10.3%); intracranial hemorrhage in 26.1%; and mimic in 2.5%. Clinical features among platinum half-hour patients were largely similar to later-treated patients and included age 69 (interquartile range, 57-79), 44.8% women, prehospital Los Angeles Motor Scale median 4 (3-5), and early-postarrival National Institutes of Health Stroke Scale deficit 8 (interquartile range, 3-18). Platinum half-hour acute cerebral ischemia patients did have more severe prehospital motor deficits and younger age; platinum half-hour intracranial hemorrhage patients had more severe motor deficits, were more often female, and less often of Hispanic ethnicity. Outcomes at 3 m in platinum half-hour patients were comparable to later-treated patients and included freedom-from-disability (modified Rankin Scale score, 0-1) in 35.5%, functional independence (modified Rankin Scale score, 0-2) in 53.2%, and mortality in 17.7%. Prehospital initiation permits treatment start within the platinum half-hour after last known well in a substantial proportion of acute ischemic and hemorrhagic stroke patients, accounting for more than 1 in 10 enrolled in a multicenter trial. Hyperacute platinum half-hour patients were largely similar to later-treated patients and are an attainable target for treatment in prehospital stroke trials.

Sections du résumé

BACKGROUND
To emphasize treatment speed for time-sensitive conditions, emergency medicine has developed not only the concept of the golden hour, but also the platinum half-hour. Patients with acute stroke treated within the first half-hour of onset have not been previously characterized.
METHODS
In this cohort study, we analyzed patients enrolled in the FAST-MAG (Field Administration of Stroke Therapy-Magnesium) trial, testing paramedic prehospital start of neuroprotective agent ≤2 hours of onset. The features of all acute cerebral ischemia, and intracranial hemorrhage patients with treatment starting at ≤30 m of last known well were compared with later-treated patients.
RESULTS
Among 1680 patients, 203 (12.1%) received study agents within 30 minutes of last known well. Among platinum half-hour patients, median onset-to-treatment time was 28 minutes (interquartile range, 25-30), and final diagnoses were acute cerebral ischemia in 71.8% (ischemic stroke, 61.5%, TIA 10.3%); intracranial hemorrhage in 26.1%; and mimic in 2.5%. Clinical features among platinum half-hour patients were largely similar to later-treated patients and included age 69 (interquartile range, 57-79), 44.8% women, prehospital Los Angeles Motor Scale median 4 (3-5), and early-postarrival National Institutes of Health Stroke Scale deficit 8 (interquartile range, 3-18). Platinum half-hour acute cerebral ischemia patients did have more severe prehospital motor deficits and younger age; platinum half-hour intracranial hemorrhage patients had more severe motor deficits, were more often female, and less often of Hispanic ethnicity. Outcomes at 3 m in platinum half-hour patients were comparable to later-treated patients and included freedom-from-disability (modified Rankin Scale score, 0-1) in 35.5%, functional independence (modified Rankin Scale score, 0-2) in 53.2%, and mortality in 17.7%.
CONCLUSIONS
Prehospital initiation permits treatment start within the platinum half-hour after last known well in a substantial proportion of acute ischemic and hemorrhagic stroke patients, accounting for more than 1 in 10 enrolled in a multicenter trial. Hyperacute platinum half-hour patients were largely similar to later-treated patients and are an attainable target for treatment in prehospital stroke trials.

Identifiants

pubmed: 35545939
doi: 10.1161/STROKEAHA.121.036993
pmc: PMC9329219
mid: NIHMS1801877
doi:

Substances chimiques

Platinum 49DFR088MY

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2426-2434

Subventions

Organisme : NINDS NIH HHS
ID : U01 NS044364
Pays : United States

Références

J Thorac Oncol. 2010 Sep;5(9):1315-6
pubmed: 20736804
Stroke. 2020 Nov;51(11):3425-3432
pubmed: 33104466
JAMA. 2016 Sep 27;316(12):1279-88
pubmed: 27673305
Bioinformatics. 2018 Oct 1;34(19):3365-3376
pubmed: 29726967
JAMA. 2013 Jun 19;309(23):2480-8
pubmed: 23780461
Soins. 2014 Sep;(788):14-5
pubmed: 25464628
Stroke. 2006 Jan;37(1):263-6
pubmed: 16339467
N Engl J Med. 2015 Feb 5;372(6):528-36
pubmed: 25651247
Circulation. 2017 Jan 10;135(2):128-139
pubmed: 27815374
Stroke. 2007 Nov;38(11):3097-115
pubmed: 17901393
JAMA Neurol. 2015 Jan;72(1):25-30
pubmed: 25402214
Stroke. 2009 Mar;40(3):833-40
pubmed: 19150875
Lancet Neurol. 2019 Jan;18(1):46-55
pubmed: 30413385
Int J Stroke. 2014 Feb;9(2):220-5
pubmed: 24444117
Emerg Med J. 2013 Dec;30(12):1048-55
pubmed: 23258373
Lancet. 2014 Nov 29;384(9958):1929-35
pubmed: 25106063
Stroke. 2016 Jun;47(6):1651-3
pubmed: 27143274
Stroke. 2020 Aug;51(8):2553-2557
pubmed: 32611286
Int J Stroke. 2014 Feb;9(2):215-9
pubmed: 24444116
JAMA. 2019 Jul 16;322(3):252-263
pubmed: 31310296
West J Emerg Med. 2014 Mar;15(2):251-9
pubmed: 24926394

Auteurs

Anantbir S Randhawa (AS)

California University of Science and Medicine, School of Medicine, Colton (A.S.R.).

Fatima Pariona-Vargas (F)

National University of Cajamarca, School of Medicine, Cajamarca, Peru (F.P.-V.).

Sidney Starkman (S)

Departments of Emergency Medicine and Neurology (S.S., S.S.), University of California Los Angeles David Geffen School of Medicine.

Nerses Sanossian (N)

Department of Neurology University of Southern California, Los Angeles (N.S., M.K.-T.).

David S Liebeskind (DS)

Department of Neurology (D.S.L., G.A., L.S., L.R.-J., M.V.-S., J.L.S.), University of California Los Angeles David Geffen School of Medicine.

Gilda Avila (G)

Department of Neurology (D.S.L., G.A., L.S., L.R.-J., M.V.-S., J.L.S.), University of California Los Angeles David Geffen School of Medicine.

Samuel Stratton (S)

Departments of Emergency Medicine and Neurology (S.S., S.S.), University of California Los Angeles David Geffen School of Medicine.

Jeffrey Gornbein (J)

Department of Computational Medicine, University of California, Los Angeles (J.G.).

Latisha Sharma (L)

Department of Neurology (D.S.L., G.A., L.S., L.R.-J., M.V.-S., J.L.S.), University of California Los Angeles David Geffen School of Medicine.

Lucas Restrepo-Jimenez (L)

Department of Neurology (D.S.L., G.A., L.S., L.R.-J., M.V.-S., J.L.S.), University of California Los Angeles David Geffen School of Medicine.

Miguel Valdes-Sueiras (M)

Department of Neurology (D.S.L., G.A., L.S., L.R.-J., M.V.-S., J.L.S.), University of California Los Angeles David Geffen School of Medicine.

May Kim-Tenser (M)

Department of Neurology University of Southern California, Los Angeles (N.S., M.K.-T.).

Pablo Villablanca (P)

Department of Neuroradiology (P.V.), University of California Los Angeles David Geffen School of Medicine.

Robin Conwit (R)

National Institute of Neurological Disorders and Stroke, National Institutes of Health, Neuroscience Center, Bethesda, MD (R.C.).

Scott Hamilton (S)

Department of Neurology, Stanford University, Palo Alto, CA (S.H.).

Jeffrey L Saver (JL)

Department of Neurology (D.S.L., G.A., L.S., L.R.-J., M.V.-S., J.L.S.), University of California Los Angeles David Geffen School of Medicine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH